<DOC>
	<DOC>NCT01030315</DOC>
	<brief_summary>Study design: - Phase I, first-in-human, randomized, double-blind, placebo-controlled, sequential dose escalation study of intravenously administered HM10760A in healthy adult Caucasian and Japanese subjects. Up to 5 dose level cohorts are planned. In each dose level cohort, subjects will be randomized to receive a single dose of HM10760A or placebo. Primary Objective: - To evaluate safety profile of single intravenous (IV) dose levels of HM10760A in healthy adult Caucasian and Japanese subjects.</brief_summary>
	<brief_title>A Study of HM10760A (Long-acting Erythropoietin) in Healthy Adult Caucasian and Japanese Subjects</brief_title>
	<detailed_description>Secondary Objectives: - To evaluate the dose response relationship of a single IV dose of HM10760A on pharmacodynamic parameters - To assess the immunogenicity of a single IV dose of HM10760A.</detailed_description>
	<mesh_term>Epoetin Alfa</mesh_term>
	<criteria>Healthy Caucasian and Japanese male and/or female volunteers Age 18 to 55 years Hemoglobin of &gt;12 g/dL and &lt;16 g/dL for male subjects, &gt;10 g/dL and &lt;14 g/dL for female Caucasian subjects Prior exposure to EPO, darbepoetin, other EPO support proteins hypersensitivity to EPO, darbepoetin, E.coli derived proteins Hemoglobinopathy SBP &gt; 140 mmHg or &lt; 90 mmHg or DBP &gt; 95 mmHg Chronic, uncontrolled, or symptomatic inflammatory disease Malignancy(except nonmelanoma skin cancer)</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>February 2014</verification_date>
	<keyword>Erythropoietin</keyword>
	<keyword>Long-acting</keyword>
	<keyword>EPO</keyword>
</DOC>